Tekla Capital Management LLC Intercept Pharmaceuticals, Inc. Transaction History

Tekla Capital Management LLC

  • $2.53 Billion
  • Q2 2023

A detailed history of Tekla Capital Management LLC transactions in Intercept Pharmaceuticals, Inc. stock. As of the latest transaction made, Tekla Capital Management LLC holds 52,067 shares of ICPT stock, worth $0. This represents 0.02% of its overall portfolio holdings.

Number of Shares
52,067
Previous 52,067 -0.0%
Holding current value
$0
Previous $699,000 17.74%
% of portfolio
0.02%
Previous 0.03%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021
SELL
$12.99 - $20.47 $324,750 - $511,750
-25,000 Reduced 32.44%
52,067 $773,000
Q2 2020

Aug 13, 2020
BUY
$46.7 - $92.04 $1.99 Million - $3.93 Million
42,653 Added 123.94%
77,067 $3.69 Million
Q3 2019

Nov 13, 2019
SELL
$58.69 - $80.46 $1.14 Million - $1.56 Million
-19,443 Reduced 36.1%
34,414 $2.28 Million
Q2 2019

Aug 14, 2019
SELL
$77.77 - $120.68 $421,357 - $653,844
-5,418 Reduced 9.14%
53,857 $4.29 Million
Q1 2019

May 14, 2019
BUY
$91.83 - $120.68 $4.22 Million - $5.54 Million
45,927 Added 344.07%
59,275 $6.63 Million
Q4 2018

Feb 13, 2019
BUY
$85.79 - $126.46 $1.15 Million - $1.69 Million
13,348 New
13,348 $1.35 Million
Q4 2017

Feb 14, 2018
SELL
$58.2 - $72.76 $7.17 Million - $8.96 Million
-123,200 Closed
0 $0
Q3 2017

Nov 13, 2017
BUY
$57.01 - $118.75 $7.02 Million - $14.6 Million
123,200
123,200 $7.15 Million

Others Institutions Holding ICPT

# of Institutions
6
Shares Held
1.04M
Call Options Held
30K
Put Options Held
5.9K
View Full List

About INTERCEPT PHARMACEUTICALS, INC.

ICPT Quotes by TradingView
  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email